{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:27:01Z","timestamp":1772857621375,"version":"3.50.1"},"reference-count":38,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,10,29]],"date-time":"2021-10-29T00:00:00Z","timestamp":1635465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NCI R01CA151708"],"award-info":[{"award-number":["NIH\/NCI R01CA151708"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA023074"],"award-info":[{"award-number":["P30 CA023074"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NCI P01 CA041108"],"award-info":[{"award-number":["NIH\/NCI P01 CA041108"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH\/NCI R01CA151708 ("],"award-info":[{"award-number":["NIH\/NCI R01CA151708 ("]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>Oxylipins derived from arachidonic acid (ARA) have been implicated in the development of colorectal adenomas and colorectal cancer. The primary purpose of this work was to determine the relationship between plasma levels of oxylipins and colorectal adenoma characteristics at study entry, as well as with the development of a new adenoma during follow-up within a Phase III adenoma prevention clinical trial with selenium (Sel). Secondarily, we sought to determine whether the selenium intervention influenced plasma oxylipin levels. Four oxylipins were quantified in stored plasma samples from a subset of Sel study subjects (n = 256) at baseline and at 12-months. There were significantly lower odds of an advanced adenoma at baseline with higher prostaglandin E2 (PGE2), with an OR (95% CI) of 0.55 (0.33\u20130.92), and with 5-hydroxyeicosatetraenoic acid (5-HETE) ((0.53 (0.33\u20130.94)); and of a large adenoma with higher PGE2 ((0.52 (0.31\u20130.87)). In contrast, no associations were observed between any oxylipin and the development of a new adenoma during follow-up. Selenium supplementation was associated with a significantly smaller increase in 5-HETE after 12 months compared to the placebo, though no other results were statistically significant. The ARA-derived oxylipins may have a role in the progression of non-advanced adenoma to advanced, but not with the development of a new adenoma.<\/jats:p>","DOI":"10.3390\/nu13113877","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T22:24:22Z","timestamp":1635805462000},"page":"3877","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["A Protective Role for Arachidonic Acid Metabolites against Advanced Colorectal Adenoma in a Phase III Trial of Selenium"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5811-1019","authenticated-orcid":false,"given":"Jessica A.","family":"Martinez","sequence":"first","affiliation":[{"name":"Department of Nutritional Sciences, University of Arizona, Tucson, AZ 85721, USA"},{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-5575","authenticated-orcid":false,"given":"Meghan B.","family":"Skiba","sequence":"additional","affiliation":[{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H-H. Sherry","family":"Chow","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wade M.","family":"Chew","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathylynn","family":"Saboda","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lance","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"},{"name":"Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4231-502X","authenticated-orcid":false,"given":"Nathan A.","family":"Ellis","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"},{"name":"Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ 85724, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth T.","family":"Jacobs","sequence":"additional","affiliation":[{"name":"University of Arizona Cancer Center, Tucson, AZ 85724, USA"},{"name":"Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00281-012-0342-8","article-title":"Multifaceted roles of PGE2 in inflammation and cancer","volume":"35","author":"Nakanishi","year":"2013","journal-title":"Semin Immunopathol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/CEJ.0000000000000245","article-title":"Dietary patterns and colorectal cancer risk: A meta-analysis","volume":"26","author":"Feng","year":"2017","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1753-4887.2010.00299.x","article-title":"Dietary patterns and the risk of colorectal cancer and adenomas","volume":"68","author":"Randi","year":"2010","journal-title":"Nutr. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1097\/PPO.0000000000000003","article-title":"An inflammatory mediator, prostaglandin E2, in colorectal cancer","volume":"19","author":"Wang","year":"2013","journal-title":"Cancer J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1158\/1940-6207.CAPR-11-0426","article-title":"Urinary prostaglandin E2 metabolite and risk for colorectal adenoma","volume":"5","author":"Shrubsole","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1158\/1940-6207.CAPR-14-0120","article-title":"Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs","volume":"7","author":"Bezawada","year":"2014","journal-title":"Cancer Prev. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1200\/JCO.2006.06.4931","article-title":"Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk","volume":"24","author":"Cai","year":"2006","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/carcin\/bgp014","article-title":"The COX-2\/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment","volume":"30","author":"Greenhough","year":"2009","journal-title":"Carcinogenesis"},{"key":"ref_9","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"Armaghany","year":"2012","journal-title":"Gastrointest Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"U.S. Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D.C., Curry, S.J., Davidson, K.W., Epling, J.W., Garcia, F.A.R., Gillman, M.W., Harper, D.M., and Kemper, A.R. (2016). Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 315, 2564\u20132575.","DOI":"10.1001\/jama.2016.5989"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1038\/ctg.2016.47","article-title":"Influence of Genetic Polymorphisms in Prostaglandin E2 Pathway (COX-2\/HPGD\/SLCO2A1\/ABCC4) on the Risk for Colorectal Adenoma Development and Recurrence after Polypectomy","volume":"7","author":"Pereira","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1002\/gcc.22042","article-title":"Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia","volume":"52","author":"Kleinstein","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_13","first-page":"243","article-title":"Targeting 20-HETE producing enzymes in cancer\u2014rationale, pharmacology, and clinical potential","volume":"6","author":"Alexanian","year":"2013","journal-title":"Onco Targets Ther."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Thompson, P.A., Ashbeck, E.L., Roe, D.J., Fales, L., Buckmeier, J., Wang, F., Bhattacharyya, A., Hsu, C.H., Chow, H.H., and Ahnen, D.J. (2016). Selenium Supplementation for Prevention of Colorectal Adenomas and Risk of Associated Type 2 Diabetes. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djw152"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Thompson, P.A., Ashbeck, E.L., Roe, D.J., Fales, L., Buckmeier, J., Wang, F., Bhattacharyya, A., Hsu, C.H., Chow, S.H., and Ahnen, D.J. (2016). Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djw151"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1158\/1940-6207.CAPR-12-0204","article-title":"Design and baseline characteristics of participants in a phase III randomized trial of celecoxib and selenium for colorectal adenoma prevention","volume":"5","author":"Thompson","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial","volume":"352","author":"Bresalier","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","article-title":"Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: The cross trial safety analysis","volume":"117","author":"Solomon","year":"2008","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"8085","DOI":"10.1021\/ac901282n","article-title":"Quantitative profiling method for oxylipin metabolome by liquid chromatography electrospray ionization tandem mass spectrometry","volume":"81","author":"Yang","year":"2009","journal-title":"Anal. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s11306-012-0417-5","article-title":"Serum oxylipin profiles in IgA nephropathy patients reflect kidney functional alterations","volume":"8","author":"Zivkovic","year":"2012","journal-title":"Metabolomics"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e00131","DOI":"10.1002\/prp2.131","article-title":"Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses","volume":"3","author":"Keizer","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-3016.2008.00969.x","article-title":"Assays with lower detection limits: Implications for epidemiological investigations","volume":"22","author":"Whitcomb","year":"2008","journal-title":"Paediatr. Perinat. Epidemiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"370","DOI":"10.4161\/cbt.1.4.9","article-title":"Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines","volume":"1","author":"Baines","year":"2002","journal-title":"Cancer Biol. Ther."},{"key":"ref_24","first-page":"1358","article-title":"Urine PGE-M: A metabolite of prostaglandin E2 as a potential biomarker of advanced colorectal neoplasia","volume":"4","author":"Johnson","year":"2006","journal-title":"Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/mc.22367","article-title":"Evaluation of pro-inflammatory markers plasma C-reactive protein and urinary prostaglandin-E2 metabolite in colorectal adenoma risk","volume":"55","author":"Davenport","year":"2016","journal-title":"Mol. Carcinog"},{"key":"ref_26","first-page":"111","article-title":"Serum concentrations of fatty acids and colorectal adenoma risk: A case-control study in Japan","volume":"9","author":"Ghadimi","year":"2008","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1158\/1055-9965.EPI-06-0346","article-title":"Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer","volume":"16","author":"Hall","year":"2007","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/aje\/kwi066","article-title":"Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: A prospective study","volume":"161","author":"Kojima","year":"2005","journal-title":"Am. J. Epidemiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1002\/ijc.23729","article-title":"Opposing associations of serum n-3 and n-6 polyunsaturated fatty acids with colorectal adenoma risk: An endoscopy-based case-control study","volume":"123","author":"Pot","year":"2008","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1017\/S0007114517001490","article-title":"PUFA levels in erythrocyte membrane phospholipids are differentially associated with colorectal adenoma risk","volume":"117","author":"Rifkin","year":"2017","journal-title":"Br. J. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12033","DOI":"10.1038\/s41598-019-48381-0","article-title":"Arachidonic acid-derived hydroxyeicosatetraenoic acids are positively associated with colon polyps in adult males: A cross-sectional study","volume":"9","author":"Yin","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"10057","DOI":"10.1158\/0008-5472.CAN-06-1814","article-title":"Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells","volume":"66","author":"Hwang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"17964","DOI":"10.1074\/jbc.M703075200","article-title":"The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta12,14-prostaglandin J2 in macrophages","volume":"282","author":"Vunta","year":"2007","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1055\/s-0029-1220724","article-title":"Selenium and inflammation: Underlying anti-inflammatory mechanisms","volume":"41","author":"Duntas","year":"2009","journal-title":"Horm. Metab. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00394-009-0012-3","article-title":"Regulation of expression of apolipoprotein A-I by selenium status in human liver hepatoblastoma cells","volume":"48","author":"Stahle","year":"2009","journal-title":"Eur. J. Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/carcin\/21.4.617","article-title":"Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate","volume":"21","author":"Rao","year":"2000","journal-title":"Carcinogenesis"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/10409238.2020.1717430","article-title":"Selenium and selenoproteins in prostanoid metabolism and immunity","volume":"54","author":"Qian","year":"2019","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.bbrc.2004.01.100","article-title":"Rapid induction of apoptosis in prostate cancer cells by selenium: Reversal by metabolites of arachidonate 5-lipoxygenase","volume":"315","author":"Ghosh","year":"2004","journal-title":"Biochem. Biophys. Res. Commun"}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/11\/3877\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:22:41Z","timestamp":1760167361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/13\/11\/3877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,29]]},"references-count":38,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["nu13113877"],"URL":"https:\/\/doi.org\/10.3390\/nu13113877","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,29]]}}}